- Home
- SPT vs RCKT Comparison
SPT vs RCKT Comparison
Compare SPT & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPT
- RCKT
- Stock Information
- Founded
- SPT 2010
- RCKT 1999
- Country
- SPT United States
- RCKT United States
- Employees
- SPT N/A
- RCKT N/A
- Industry
- SPT Computer Software: Prepackaged Software
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- SPT Technology
- RCKT Health Care
- Exchange
- SPT Nasdaq
- RCKT Nasdaq
- Market Cap
- SPT 799.3M
- RCKT 328.6M
- IPO Year
- SPT 2019
- RCKT N/A
- Fundamental
- Price
- SPT $14.75
- RCKT $3.19
- Analyst Decision
- SPT Buy
- RCKT Buy
- Analyst Count
- SPT 10
- RCKT 13
- Target Price
- SPT $27.70
- RCKT $12.96
- AVG Volume (30 Days)
- SPT 954.9K
- RCKT 5.7M
- Earning Date
- SPT 11-06-2025
- RCKT 11-06-2025
- Dividend Yield
- SPT N/A
- RCKT N/A
- EPS Growth
- SPT N/A
- RCKT N/A
- EPS
- SPT N/A
- RCKT N/A
- Revenue
- SPT $430,795,000.00
- RCKT N/A
- Revenue This Year
- SPT $13.01
- RCKT N/A
- Revenue Next Year
- SPT $11.79
- RCKT $108.43
- P/E Ratio
- SPT N/A
- RCKT N/A
- Revenue Growth
- SPT 14.79
- RCKT N/A
- 52 Week Low
- SPT $13.33
- RCKT $2.19
- 52 Week High
- SPT $36.30
- RCKT $22.01
- Technical
- Relative Strength Index (RSI)
- SPT 46.44
- RCKT 49.21
- Support Level
- SPT $13.80
- RCKT $3.09
- Resistance Level
- SPT $15.56
- RCKT $3.29
- Average True Range (ATR)
- SPT 0.64
- RCKT 0.16
- MACD
- SPT 0.05
- RCKT -0.02
- Stochastic Oscillator
- SPT 48.39
- RCKT 20.03
About SPT Sprout Social Inc
Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.